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Abstract
A novel VP-16 derivative, 4β-[N -(4‴-acetyloxyl-phenyl-1‴-carbonyl)-4″-aminoanilino]-4 ′-O-demethyl-4-
desoxypodophyllotoxin (GL3), displayed a wide range of cytotoxicity in a panel of human tumor cell lines, with
half-maximal inhibitory concentration (IC50) values ranging from 0.82 to 4.88 μM, much less than that of VP-16
(4.18–39.43 μM). Importantly, GL3 induces more significant apoptosis and cell cycle arrest than VP-16. Themolecular
and cellular machinery studies showed that GL3 functions as a topoisomerase II (Top 2) poison through direct binding to
the enzyme, and the advanced cell-killing activities of GL3 were ascribed to its potent effects on trapping Top 2–DNA
cleavage complex, Moreover, GL3-triggered DNA double-strand breaks and apoptotic cell death were in a Top 2–
dependent manner, because the catalytic inhibitor aclarubicin attenuated these biologic consequences caused by
Top 2 poisoning inGL3-treated cells. Taken together, among a series of 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin
analog, GL3 stood out by its improved anticancer activity and well-defined Top 2 poisoning mechanisms, which
merited the potential value of GL3 as an anticancer lead compound/drug candidate deserving further development.
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Introduction
DNA topoisomerase II (Top 2) solves the topological problems of
DNA in replication, transcription, recombination, chromosome
condensation, and decondensation by mediating the ATP-dependent
induction of coordinated nicks in both strands of the DNA duplex,
followed by crossing of another double-strand DNA through the
transiently broken duplex [1,2]. Given the ability to interfere with
this essential enzyme has been proved to be effective strategy for
cancer therapy, Top 2 is regarded as an excellent target of anticancer
drugs [2,3].
A wide range of Top 2–targeted inhibitors are commonly classi-
fied as Top 2 poisons and catalytic inhibitors [3,4]; among them,
the poisons that are recognized to interrupt the breakage/reunion
reaction of the enzyme, resulting in the accumulation of Top 2–DNA
covalent intermediate, the cleavage complex, and causing cancer
cell death, attracts more attention in terms of cancer-killing capa-
bility [2,3]. One of the most widely used Top 2 poisons, etoposide
(VP-16), acts by trapping the Top 2 cleavage complex, induces a
high level of DNA damage and subsequent apoptosis [5], and
was officially approved for clinical use against various types of
cancers including breast cancer, testicular cancer, small cell lung
cancer, lymphoma, Kaposi’s sarcoma, and childhood leukemia
[6,7]. In contrast, those agents that functioned as Top 2 catalytic
inhibitors generally imposed limited anticancer activity against the
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cancer cells but displayed abrogation effects on Top 2 poison(s)–caused
cleavage complex formation, DNA double-strand breaks (DSBs),
cell cycle, and apoptosis [4]. Consequently, all the Top 2–targeted
anticancer drugs clinically used for their antitumor activities belong
to Top 2 poisons. Over the past decades, increasing research is
focused on the development of novel Top 2 poisons, for their supe-
riority in apoptotic induction and cancer cell–killing capabilities.
4β-[N -(4‴-acetyloxyl-phenyl-1‴-carbonyl)-4″-aminoanilino]-4′-
O-demethyl-4-desoxypodophyllotoxin (GL3) was developed as a
novel 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin analog
with potential anticancer activities and undefined mechanism(s)
(Figure 1A ) [8]. Preliminary data showed that GL3 was a promising
anticancer agent that can be orally administered and significantly
arrested the growth of human lung cancer 95-D xenografted tumors
on nude mice at the dosage of 50 mg/kg.
In the present study, we report the antitumor effects of GL3 on
human oral squamous carcinoma KB cells and human non–small cell
lung cancer A549 cells in vitro. Importantly, we examined the inhib-
itory profiles of GL3 on Top 2 and its subsequent events, including
G2/M arrest and apoptosis through the ataxia telangiectasia-mutated
(ATM)/ATM-Rad3-related (ATR) and mitochondria signaling path-
ways, respectively. Comparing with its parent compound VP-16,
GL3 displayed improved anticancer activity, highly active Top 2
inhibitory effects. Taken together, these results suggest the potential
value of GL3 as a novel anticancer drug candidate that deserves
further development.
Figure 1. GL3 was a novel 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin analog with anticancer activities and Top 2–targeting
effects. (A) Chemical structure of GL3. (B) The half-maximal inhibitory concentration (IC50) values of GL3 against a variety of cancer cells.
Cells were treated with serial diluted concentrations of GL3 for 72 hours, and the viability of cells was calculated using MTT assay. (C) GL3
exhibited Top 2–targeting activity as determined by kDNA decatenation assay. (D) Top 1 catalytic activity was not impacted by GL3.
MONCPT is used as a positive control. (E) The interaction between GL3 or VP16 and Top 2 was predicted by automated molecular docking.
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Materials and Methods
Reagents
GL3 was synthesized by Dr Yongzhou Hu (Zhejiang University–
Ecole Normole Superienre Joint Laboratory of Medicinal Chemistry,
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou,
China) [8]. The structure was shown in Figure 1A, and its purity was
more than 99%. Etoposide (VP-16), aclarubicin, and caffeine were
purchased from Sigma (St Louis, MO). GL3, VP-16, and aclarubicin
were dissolved in DMSO (50 mM) as stock solutions. Caffeine was
dissolved in sterilized water. The stock solutions were kept frozen in
aliquot at −20°C. The primary antibodies to chk1, chk2, phospho-
cdc25c, cdc2, cyclin B1, p53, phospho-p53, caspase-8, caspase-9,
caspase-3, polyADP-ribose polymerase (PARP), and β-actin and
HRP-labeled secondary anti-goat, anti-mouse, and anti-rabbit anti-
bodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The antibodies to cleaved caspase-3, γ-H2AX, phospho-chk2,
phospho-chk1, and phospho-cdc2 (T14/T15) were purchased from
Cell Signaling Inc (Danvers, MA). ECL was purchased from Pierce
Biotechnology (Rockford, IL).
Cell Line and Cell Culture
The human ovarian cancer A2780 cells, human prostate cancer
PC-3 cells, oral squamous carcinoma KB cells, and human gastric
carcinoma SGC-7901 cells were maintained in RPMI-1640 medium
(Invitrogen, Grand Island, NY). Human hepatocellular liver carcinoma
HepG2 cells and colorectal carcinoma HCT-116 cells were maintained
in high-glucose Dulbecco modified eagle medium (HG-DMEM) (Life
Technologies, Grand Island, NY; 2 g/l glucose). Non–small cell lung
cancer A549 cells were maintained in F12 medium (Invitrogen). All
media were supplemented with heat-inactivated FBS plus 2 mM
glutamine and 50 units/ml penicillin. All the cell lines were endowed
by Shanghai Institutes for Biological Sciences (Chinese Academy of
Sciences, Shanghai, China) and incubated at 37°C in 5% CO2.
Cell Proliferation Assay
Cells were seeded in 96-well plates at 4 × 103 cells/well. After
24 hours, GL3 or VP-16 at a series of concentrations (0–50 μM)
was added to each well, and then the cells were incubated for
72 hours. At the end of the treatment, the cells were incubated for
another 4 hours after 5.0 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma) was added. A quantity
of 100 μl of DMSO was added to each well to dissolve the purple
formazan crystals. Then, cell viability was obtained by measuring the
absorbance on an automated microplate spectrophotometer (Bio-Tek
Instruments, Winooski, VT) at 570 nm. The growth inhibition was
calculated according to the following formula: The Growth Inhibition
Ratio (IR%) = (1 − OD570 treated /OD570 control ) × 100%.
kDNA Decatenation Assay
The detection of Top 2–mediated cleavage-religation complex
stabilization was performed using the Topoisomerase II Assay Kit
(TopoGEN, Inc, Port Orange, FL; Catalog No. TG1001-1). The
Top 2 assay reaction buffer consisting of 2 mM ATP, 0.05 M
Tris-HCl (pH 8.0), 0.15 M NaCl, 10 mM MgCl2, and 0.5 mM
dithiothreitol was mixed with 0.1 μg of kDNA. Reactions are assem-
bled in tubes with water, buffer, and kDNA. The test fractions were
added last and the reactions incubated at 37°C for 30 minutes. After
termination with stop buffer, samples were run on electrophoresis
in a 2% agarose gel in 1× TAE at 50 V for 2 hours and stained with
0.5 mg/ml ethidium bromide to facilitate visualization by fluores-
cence under UV light. Images were photographed by Bio-Rad
GD2000 (Bio-Rad, Hercules, CA).
Top 1–Mediated Supercoiled pBR322 Relaxation
DNA relaxation assay was done to evaluate the effects on Top 1
activity. The reaction buffer contained 35 mM Tris-HCl (pH 8),
72 mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM spermidine,
0.01% BSA, 0.5 μg of supercoiled pBR322 DNA, and 1 unit of
Top 1 (GE Healthcare, Buckinghamshire, England) in a total vol-
ume of 20 μl. Reaction mixtures were incubated at 37°C for 30 min-
utes in the presence of drugs and terminated by adding 10% sodium
dodecyl sulfate.
Molecular Docking of Top 2–DNA Complex and GL3/VP-16
In an attempt to understand the molecular interaction between
GL3 and Top 2, a molecular docking study was performed using
the Discovery Studio 2.1/CDOCKER protocol. The crystal structure
of Top 2/G-segment DNA complex (PDB ID: 2RGR) was used as
the template. Docking and subsequent scoring studies were per-
formed using default parameters.
Western Blot Analysis
Proteins of A549 and KB cells were extracted in RIPA buffer
(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% sodium
dodecyl sulfate, 0.5% deoxycholic acid, 0.02% sodium azide, 1%
NP-40, 2.0 μg/ml aprotinin, and 1 mM PMSF). For each lane, 40.0 to
80.0 μg of total protein (equal amount) was loaded. After being fraction-
ated on 8% to 15%Tris-glycine gels, proteins were transferred onto poly-
vinylidene fluoride (PVDF) membrane (Millipore Corporation, Billerica,
MA) and probed with primary antibodies and then HRP-labeled sec-
ondary antibodies. Finally, proteins were visualized using ECL.
Neutral Single-Cell Gel Electrophoresis Assay
Cells (5 × 105/ml) were treated with GL3 for indicated times.
DNA DSBs were evaluated by neutral single-cell gel electrophoresis
assay, which was done according to the method with slight modifica-
tions [9]. Images were captured using fluorescent microscope (Leica
Microsystems, Wetzlar, Germany).
Flow Cytometry Analysis of DNA Content
Exponentially growing cells (2 × 106) were seeded at 4 × 105 cells/
flask in 75-cm2 flasks. The cells were cultured at 37°C in a 5% CO2
atmosphere for 24 hours before they were exposed to GL3 or VP-16.
Cells were harvested, washed, and resuspended in 500 μl of phosphate-
buffered saline containing 50.0 μg/ml RNaseA (Amersco, Solon, OH).
After incubation for 30 minutes, the cells were stained with 10.0 μg/ml
propidium iodide (PI; Sigma) in the dark for 30 minutes. Flow
cytometry was performed on FACSCalibur (BD Biosciences, San
Jose, CA), and then the data were analyzed using CellQuest software
(BD Biosciences).
Results
GL3 Arrests Cancer Cell Proliferation In Vitro
The antiproliferative activity of GL3 was determined on various
human tumor cell lines. As shown in Figure 1B, GL3 displayed wide
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potent concentration-dependent cytotoxicity in a diversity of human
cancer cell lines including ovarian cancer, prostate cancer, colorectal
cancer, gastric carcinoma, oral squamous carcinoma, hepatocellular
liver carcinoma, and lung cancer without significant tissue specificity.
Different degrees of antiproliferative effect on these cells based on
IC50 values of GL3 were shown as a range from 0.82 to 4.88 μM,
much less than VP-16 (4.18–39.43 μM). In particular, among all the
tested tumor cells, GL3 exhibited most potent growth inhibitory
effects against KB cells, and in A549 cells, the IC50 values for GL3
and VP-16 achieved a maximum difference; thus, these two cell lines
were chosen for our further research.
GL3 Targets Top 2 through Binding with the Active Site and
Inhibiting the Catalytic Activity
To determine the effects of GL3 on Top 2, the putative cellular
target of VP-16, kDNA decatenation assays was first employed to
examine the Top 2 catalytic activity with or without GL3 and VP-16.
kDNA would be catalytically degraded into nicked circular DNA and
relaxed circular DNA in the presence of Top 2 and ATP. As shown in
Figure 1C , both GL3 and VP-16 inhibited the activity of Top 2 when
measured by a loss in its capacity to decatenate kDNA. Intensity of
nicked circular DNA diminished in a concentration-dependent manner
in both VP-16 and GL3 groups, indicating the comparable inhibitory
effects of these two compounds on the Top 2 catalytic activity.
To help clarify the mechanism(s) that GL3 inhibits Top 2 catalytic
activity, we used automated molecular docking to predict the confor-
mation of GL3 and VP-16 when bound to Top 2. The most probable
binding conformations of these two compounds were obtained, and
we noticed that GL3 made several important interactions along the
active site of Top 2 with different mode in comparison with VP-16
as shown in Figure 1E . The binding energy of compound GL3 was
stronger than that of VP-16. Ranking according to Dock energy and
conformational analyses together indicate that comparing with VP-16,
the different binding modes and the higher affinity for the Top 2 of
GL3 may explain the observation that GL3 showed more potent anti-
proliferative activity than that of VP-16.
Collectively with our finding that GL3 or VP-16 imposed no effects
on Top 1–mediated DNA relaxation (MONCPT, a reported CPT
derivative [10] served as a positive control; Figure 1D), these results
indicated that GL3 exhibited Top 2–targeted activity as indicated by
the comparable inhibition of catalytic activity and the distinct inter-
active binding mode with Top 2.
GL3 Induces DNA DSBs
As demonstrated by previous report that VP-16 trapped Top 2–
DNA complexes and lead to the subsequent DNA DSBs, we were
inspired to speculate that GL3 may also exert Top 2 poisoning effects
and result in DNA DSBs.
Though there are a lot of experimental results that point to the
validity of certain models, the phosphorylation of histone H2AX
(noted as γ-H2AX) within seconds after occurrence of DSBs is gen-
erally accepted. As a result, the levels of γ-H2AX were monitored to
detect the generation of DNA DSBs. As shown in Figures 2A and
3A, γ-H2AX was upregulated in A549 and KB cells after incubation
with GL3 for 2 hours.
The neutral single-cell gel electrophoresis assay (also known as
neutral comet assay) is also widely employed to detect DNA damage
at the level of the individual eukaryotic cell. Using this assay, we
found that the exposure of A549 and KB cells to GL3 within 2 hours
generated longer comet tails than that of VP-16 groups (Figures 2B
and 3B ), suggesting that GL3 induced extensive DNA DSBs, with
higher extent than that of VP-16.
In contrast, VP-16 elicited much less phosphorylation of H2AX or
comet tails under our experimental conditions (20 μM, 2 hours),
which was probably owing to the lower concentration we used than
the previous report [9]. For DNA damage detection, the reason we
Figure 2. GL3 induced DNA DSBs and G2/M arrest in A549 cells. (A) GL3 (5–20 μM, 2 hours) triggered phosphorylation of H2Ax (γ-H2Ax)
in A549 cells. (B) GL3 induced DNA DSBs in A549 cells. Cells were untreated or treated with GL3 (20 μM) for 2 hours. Detection of DSBs
was done using the neutral comet assay. Representative comet images were shown. (C) Cell cycle distribution histogram of A549 cells
treated with GL3 from the concentration of 125 to 500 nM for 24 hours, representative of three independent experiments. (D) Cell cycle
regulating pathways were activated by GL3 treatment in A549 cells.
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exposed cells with higher concentration than the IC50 values of GL3
achieved from cell proliferation assay was that when detecting DNA
damage, we exposed cells to GL3 for much shorter time than that in cell
proliferation assays (2 hours for DNA damage detection and 72 hours
for cell proliferation assay).
GL3 Induces DSB-Mediated G2/M Arrest at
Low Concentrations
Top 2 poisons generally induce cell cycle arrest owing to the gen-
eration of DNA DSBs. In the current study, the cell cycle distribution
of GL3-treated A549 and KB cells was determined. GL3 induced G2/
M arrest in a concentration-dependent manner (Figures 2C and
3C ). Most of the cells were arrested in the G2/M phase in A549
and KB cells after a 24-hour treatment (51.20% for 500 nM in
A549 cells and 84.83% for 100 nM in KB cells).
Furthermore, the levels of proteins involved in the regulation of
the G2/M transition in A549 and KB cells were examined to explore
the underlying mechanism of GL3-induced G2/M arrest. GL3
increased the levels of the phosphorylated Chk2 (T68) and did not
change the protein level of Chk2 (Figure 2D), implying the activation
of Chk2 pathway(s). In addition, in a concentration-dependent
manner, GL3 increased the protein level of cyclin B1 and the putative
inhibitory phosphorylation on Cdc2 (T14/T15) (Figures 2D and 3D).
Taken together, these results indicated that the predominant
changes in the expression of G2/M regulatory proteins caused by
GL3 treatment were induced through the Chk2 signaling pathway,
which subsequently lead to G2/M arrest in A549 and KB cells.
GL3 Causes Apoptosis in a Caspase-Dependent Manner
Most chemotherapeutic agent including Top 2–targeted drugs kill
tumor cells through apoptosis induction. In this context, flow cyto-
metry analysis after PI staining was applied to investigate the apoptosis-
inducing effects of GL3. We found that GL3 induced apoptosis in
A549 and KB cells in a concentration-dependent manner. More than
40% of A549 cells were detected to be apoptotic following the 24-hour
treatment of GL3 at 20 μM, whereas VP-16 at 20 μM drove only
about 10% of A549 cells to experience apoptosis (Figure 4A). In KB
cells, 10 μM GL3 caused more than 60% apoptosis in treated cells,
whereas 10 μM VP-16 elicited 40% of apoptosis (Figure 4C ).
The aforementioned result indicated that GL3 induced apoptosis in
A549 and KB cells; we were thus encouraged to explore how GL3 is
involved in the activation of apoptosis. After exposure to GL3, the levels
of p53, phospho-p53, andBaxwere elevated in a concentration-dependent
manner, indicating a possible role for p53 and Bax in a high-concentration
GL3-induced apoptosis. Furthermore, GL3 decreased the protein levels
of procaspase-8, procaspase-9, and procaspase-3 and induced the
cleavage of PARP (a major substrate of caspases) and caspase-3 in a
concentration-dependent manner (Figure 4B ). The similar results were
also observed in KB cells (Figure 4D). Cleaved caspase-3 and cleavage
of PARP increased visibly in a concentration-dependent manner,
accompanied with the decline trend of PARP expression (Figure 4D).
GL3-Triggered DNA DSB Is Attenuated by Top 2 Catalytic
Inhibitor Aclarubicin
Aclarubicin, a classic Top 2 catalytic inhibitor, specifically inhibits
the catalytic activity of Top 2 without significantly elevating the level
of cleavage complexes but is able to abrogate Top 2 poison–induced
DSBs via disrupting the formation of cleavage complexes. In this
context, aclarubicin was widely used to help validate the Top 2
poisons and the involvement of Top 2 in compound-induced effects
including DNA DSBs, cell cycle, and apoptosis. In this study, we
found that aclarubicin significantly antagonized GL3-induced
DNA DSBs in A549 and KB cells, as indicated by the reduction of
γ-H2AX level in aclarubicin-pretreated cells, comparing with GL3
monotreated group (Figure 5, A and B ). Using the single-cell gel elec-
trophoresis assay, we further demonstrated that aclarubicin could atten-
uate the generation of DNA DSBs triggered by GL3 (data not shown).
In addition, as expected, aclarubicin pretreatment counteracted GL3-
triggered apoptosis in KB cells as demonstrated by the attenuated cleav-
age of caspase-3 (Figure 5C ). Taken together, these results indicated
that GL3 acted as a Top 2 poison and inducing DNA DSBs as well
as apoptosis by stabilizing Top 2 cleavage complexes.
Figure 3. GL3 caused DNA DSBs and G2/M arrest in KB cells. (A) GL3 (2.5–10 μM, 2 hours) increased the γ-H2Ax up-regulation in
KB cells. (B) DNA DSBs as determined by neutral comet assay in KB cells exposed to vehicle or GL3 (10 μM, 2 hours). Representative
comet images were shown. (C) GL3 induced G2/M arrest in KB cells treated with GL3 from the concentration of 25 to 100 nM for 24 hours.
(D) Cdc2 activity was inhibited by GL3 treatment.
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Figure 4. GL3 elicited apoptosis in A549 and KB cells. (A) Percentage of apoptotic A549 cells after treatment of GL3 (5 to 20 μM) for
24 hours (mean ± SD, n = 3). (B) Pro–caspase-3, pro–caspase-8, and pro–caspase-9 were cleaved in GL3-treated A549 cells. A549 cells
were cultured with medium or serial diluted concentrations of GL3 (5–20 μM) for 24 hours. The expressions of PARP, pro–caspase-3,
cleaved caspase-3, pro–caspase-8, pro–caspase-9, p53, and Bax were tested. (C) GL3 caused apoptosis in KB cells. Cells were exposed
to GL3 (2.5–10 μM) for 24 hours (mean± SD, n=3), subjected to PI staining and fluorescence-activated cell sorting (FACS) analyses. (D) PARP
and pro–caspase-3 cleavage were detected in GL3 (2.5–10 μM, 24 hours)–treated KB cells.
Figure 5. DNA DSBs generated by Top 2 poisoning by GL3 mediated the G2/M arrest and apoptosis. (A) Top 2 catalytic inhibitor
aclarubicin abated γ-H2Ax upregulated by GL3. A549 cells were exposed to GL3 (20 μM) for 2 hours with or without pretreatment with
aclarubicin (50 nM) for 0.5 hour. (B) Aclarubicin (50 nM, 0.5-hour pretreatment) attenuated γ-H2Ax up-regulation in KB cells treated with
GL3 (10 μM) for 2 hours. (C) Aclarubicin (50 nM, 0.5-hour pretreatment) antagonized the cleavage of pro–caspase-3 induced by GL3
(10 μM, 24 hours) in KB cells. (D) Caffeine preincubation (2 mM, 0.5 h) abrogated the G2/M accumulation in GL3 (500 nM, 24 hours)–treated
A549 cells. G2/M population of GL3 group versus that of GL3 + caffeine group: **P < .01.
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GL3-Induced G2/M Arrest Is Antagonized by ATM/ATR
Inhibitor Caffeine
ATM/ATR, members of the phosphoinositide kinase–related
protein family, is critical for the cellular response including cell cycle
arrest and apoptosis upon genotoxic stresses, especially DNA DSBs.
To clarify whether ATM/ATR pathway was involved in GL3-
induced G2/M arrest, caffeine, a widely used ATM/ATR inhibitor,
was employed. As expected, preincubation with caffeine (2 mM,
30 minutes) caused an obvious decrease of G2/M population from
56.78 ± 3.99% to 26.59% ± 1.60% in GL3 (500 nM, 24 hours)–
treated A549 cells (Figure 5D), with significant differences. Thus, a
possible relationship between ATM/ATR pathway and GL3-induced
G2/M arrest was established, further supporting the notion that the
biologic consequences of GL3 treatment were attributed to GL3-caused
DNA DSBs.
Discussion
VP-16 was first synthesized in the 1960s and officially approved for
clinical use against various types of cancers since 1983. Despite the
crucial role in clinical cancer therapy for decades, etoposide (VP-16)
has been challenged with toxic side effects (bone marrow depression
and increased risk of secondary acute myelogenous leukemia), which
make it urgent to further optimize the structure of the analogs to
overcome the drawbacks and improve the anticancer activities. On
the basis of the structure-activity analyses, several critical features
for the Top 2–targeted activity were summarized to orient the
chemical modification of podophyllotoxin: modification on rings
A, B, D, and E made little contribution to improve Top 2 inhibitory
activity or had different biologic activities and β-D-glucopyranose
substituent on ring C is not essential, but the 4β configuration is
important for the Top 2 inhibitory activity. Thus, C4 becomes an
optimal position to significant structural modification. CoMFA
model further demonstrated that bulky substituents at C4 might
be favorable for Top 2 inhibition.
Our efforts focus on the design and screening of novel analogs
of VP-16 based on the structure-activity relationship analyses, and
Hu et al. synthesized several derivatives bearing bulky nitrous tails at
C4 side chain to conquer the limitations of the previous compounds,
of which compounds containing the 4β-anilino moiety exhibited
improved anticancer activities. On the basis of that structural feature,
amide groups were introduced to optimize activities of the compound.
Among these compounds, 4β-anilino-4′-O-demethyl-4-desoxypodophyllo-
toxin derivative named as 26c (GL3) exhibits potent cell-killing and
tumor growth–inhibiting capabilities against human lung cancer cells,
human oral squamous carcinoma cells, and human lung cancer xeno-
grafted tumors and imposes less toxicity compared with the other
derivative [8]. In the present study, we further examined the effects
of this compound on cancer cell proliferation, apoptosis, cell cycle,
and importantly, the Top 2–targeting activities and the subsequent
biologic consequences, aiming to explore the mechanism(s) by which
its anticancer abilities were exerted. We found that GL3 showed a
higher antiproliferative activity than that of VP-16, with the average
IC50 value about 10-fold lower than that for VP-16 (Figure 1B ).
Together with the previous findings that GL3 (26c) displayed potent
growth inhibition on 95-D xenografted tumors when administrated
intragastrically at 50 mg/kg two to three times per week, without sig-
nificant effects on mouse body weight [8], GL3 was demonstrated as
a promising anticancer agent both active in vitro and in vivo.
Extensive evidences reveal the impact of VP-16 and its derivatives
on Top 2. Two groups of Top 2 inhibitors are defined. Those agents
able to stabilize the covalent DNA Top 2 cleavage complex are
traditionally called Top 2 poisons, whereas agents acting on any of
the other steps in the catalytic cycle are called catalytic inhibitors.
VP-16 functions as a Top 2 poison, trapped the double-stranded
DNA cleavage normally catalyzed by Top 2, inhibits the relegation
of DNA breaks, and stabilized the DNA–Top 2 cleavage complexes,
subsequently triggering the desired anticancer effects, i.e., cell cycle
arrest, apoptosis, and proliferation inhibition [5]. Most derivatives of
VP-16 share the same target and the similar mechanisms with their
parental structure [11–13], by stabilizing the Top 2 cleavage com-
plex. To achieve maximum cancer-killing efficiency, the compounds
designed to target Top 2 are generally preferred to exert more potent
Top 2 poisoning effects. In our study, GL3 exerted differential anti-
proliferative activities against various cancer cell lines, in a similar
pattern with VP-16 (except that in HCT-116 and SGC-7901);
whether this differing effect was related to the expression level of
Top 2 needs to be investigated in further studies.
Catalytic inhibitors, the other group of Top 2–targeted agents,
are a heterogeneous group of compounds that might interfere with
the binding between DNA and Top 2 (aclarubicin and suramin),
stabilize non-covalent DNA Top 2 complexes (merbarone, ICRF-
187, and bisdioxopiperazine derivatives), or inhibit ATP binding
(novobiocin). In contrast with the observations that poisons could
induce apoptosis and act as anticancer agents, the catalytic inhibitors
generally caused limited apoptosis and accordingly regarded as
cardioprotectors (ICRF-187) or modulators to increase the efficacy
of other agents (suramin and novobiocin) [14], and interestingly, most
catalytic inhibitors (ICRF-187, ICRF-159, aclarubicin, etc.) can antag-
onize the DNA damage, apoptosis, and/or cytotoxicity of Top 2
poisons in cultured mammalian cells [15–18]. Thus, the attenuation
of DNA DSBs, apoptosis, or cytotoxicity by Top 2 catalytic inhibitors
could be used to validate that these cell-killing effects are imposed by
Top 2 poisons [9,18].
A typical catalytic inhibitor aclarubicin, which is known to inter-
calate into DNA thereby preventing the binding of Top 2 to DNA
and subsequently protecting Top 2 poison–induced DNA damage
and apoptosis [9,19,20], is introduced in the present study. Our
study showed that GL3-triggered DNA DSBs and subsequent apop-
tosis could be abolished by aclarubicin pretreatment as denoted by
the reduction of comet tails, phosphorylated H2AX, and caspase-3
cleavage, respectively, indicating the inhibition of Top 2 catalytic
activity could abate the DNA DSBs and subsequent apoptosis caused
by GL3, which was in accordance with the aforementioned reports
that Top 2 catalytic inhibitors could abrogate the effects of poisons
[16,17,19–21]. Thus, the mechanisms by which GL3 targeting Top 2
could be speculated as trapping Top 2–DNA cleavage complexes, and
in this context, the formation of the cleavage complex was critical for
GL3-triggered DNA DSBs and apoptotic cell death. In accordance
with this, greater interaction between Top 2 and GL3 predicted by
automated molecular docking further aids to explain the superior
anticancer activity in vitro achieved by GL3 than that of VP-16.
In our previous study [8], we have shown that GL3 (26c), a novel
4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivative, was
a promising agent that can be orally administered and significantly
inhibited human lung cancer growth but imposed limited toxicity
in vivo. This study aimed to explore the mechanisms of action of
GL3 and has shown for the first time that GL3 targets Top 2 by
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trapping cleavage complex, which drives DNA DSBs and leads to cell
cycle arrest and apoptosis. The appreciable pharmacologic profiles of
GL3, including well-defined antitumor activities and less toxicity, are
probably attributed to the delicate C-4″ substitution of the anilino
group at C4 position, with a favorable amide manipulation. This
superiority to the parent compound VP-16 favors GL3, a potential
anticancer drug candidate deserving of further development, and
more importantly, in turn offers a favorable approach in the explo-
ration of VP-16 structure optimization.
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